聚乙二醇干扰素α-2a联合利巴韦林治疗老年慢性丙型肝炎的疗效和安全性

郑颖颖; 范晓红; 王力芬; 田地; 霍娜; 陆海英; 吴赤红; 徐小元; 魏来

聚乙二醇干扰素α-2a联合利巴韦林治疗老年慢性丙型肝炎的疗效和安全性

1. 北京大学第一医院感染疾病科
2. 北京大学人民医院肝病研究所

基金项目:

国家十一五重大科技专项(2008ZX10002013)；国家自然科学基金(30771906)；教育部博士点基金课题(20090001110081)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 3804
- HTML全文浏览量: 16
- PDF下载量: 906
- 被引次数: 0
出版历程
- 出版日期: 2011-08-20

Efficacy and side effects of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C

Research funding:

摘要

摘要: 目的分析聚乙二醇干扰素（PEG-IFN）α-2a联合利巴韦林治疗老年慢性丙型肝炎（CHC）的疗效和安全性。方法老年CHC患者（≥60岁）（N=16）与中青年CHC患者（<60岁）（N=46）接受PEG-IFNα-2a 180μg/周,利巴韦林800～1000mg/d联合治疗。比较两组患者在基线、病毒应答和不良反应发生率等差异。结果老年患者中性粒细胞减少症和血小板减少症的发生率显著高于中青年患者[(P=0.044,OR（95%CI）=3.264（1.005～10.599）;P=0.000,OR（95%CI）=2.875（1.935～4.271）]。两组患者SVR率差异无统计学意义（P=0.131）。单因素分析结果提示CHC患者年龄与SVR率无明显关联。结论 PEG-IFNα-2a联合利巴韦林治疗老年CHC是安全有效的。
- 肝炎,丙型,慢性 /
- 干扰素α-2a /
- 利巴韦林
Abstract: Objective To evaluate the efficacy and safety of PEG-IFNα-2a plus ribavirin combination therapy on elderly patients with chronic hepatitis C.Methods Elder CHC patients (age≥60 years) (N=16) and younger CHC patients (age<60 years) (N=46) received PEG-IFNα-2a 180 μg/w combined ribavirin 800-1000 mg/d treatment.Baseline clinical characteristics, virological response and side effects were compared between the two groups.Results Elderly patients had a significant higher rate of neutropenia and thrombocytopenia than did younger patients[ (P=0.044, OR (95%CI) =3.264 (1.005-10.599) ;P=0.000, OR (95%CI) =2.875 (1.935-4.271) , respectively].Similar SVR rates were obtained in the two aged patients (40.00% vs 80.00%, P=0.131 by Fisher's exact test) .Univariate analysis indicated that age was not a factor associated with SVR.Conclusion Treatment of CHC with PEG-IFNα-2a plus ribavirin therapy was comparably effective and safe among elderly patients.
- hepatitis C /
- chronic /
- interferon alfa-2a

HTML全文

参考文献(6)

[1] 中华医学会.丙型病毒性肝炎防治指南[J].临床肝胆病杂志, 2004, 20 (4) :197-203.

[2]Ghany MG, Strader DB, Thomas DL, et al.Diagnosis, management, and treatment of hepatitis C:an updata[J].Hepatology, 2009, 49 (4) :1335-1374.

[3]Marcus EL, Tur-Kaspa R.Chronic Hepatitis C virus infection inolder adults[J].Clin Infect Dis, 2005, 41 (11) :1606-1612.

[4]Iwasaki Y, Ikeda H, Araki Y, et al.Limitation of combination therapyof interferon and ribavirin for older patients with chronic hepatitis C[J].Hepatology, 2006, 43 (1) :54-63.

[5]McHutchison JG, Manns MP, Brown RS.Strategies for managing ane-mia in hepatitis C patients undergoing antiviral therapy[J].Am J Gas-troenterol, 2007, 102 (4) :880-889.

[6]Honda T, Katano Y, Shimizu J, et al.Efficacy of peginterferon-α-2b plus ribavirin in patients aged 65 years and older with chronichepatitis[J].Liver Int, 2010, 30 (4) :527-537.

施引文献

资源附件(0)

访问统计